Biodel Inc. (BIOD) Announces Commercial Manufacturing Agreement With Emergent BioSolutions (EBS) For Glucagon Rescue Product
3/6/2014 9:31:11 AM
DANBURY, Conn., March 5, 2014 (GLOBE NEWSWIRE) -- Biodel Inc. (Nasdaq:BIOD) today announced another development in its Glucagon Emergency Management (GEM) development program with the signing of a long-term manufacturing agreement with Cangene bioPharma Inc. doing business as Emergent BioSolutions ("Emergent"). Under the agreement, Emergent will fill and finish commercial quantities of the GEM device. Financial terms of the agreement have not been disclosed.
Help employers find you! Check out all the jobs and post your resume.
comments powered by